EGFR and cancer: In a prespecified analysis among patients with EGFR-FISH+ cancers, OS was significantly improved in the cetuximab group (HR = 0.58 [0.39–0.86], P = 0.01): median OS of 11.8 months (95% CI: 8.6–13.5) and 6.1 months (95% CI: 4.2–8.7) in cetuximab and chemotherapy arms, respectively.